Lonza Announces Manufacturing License Agreement with Sumitomo Seika Chemicals Co. for 1, 2 benzisothiazolin 3-one (BIT) Preservative
- Nov 18, 2011
Basel, Switzerland -- Arch Chemicals Inc., an indirect, wholly owned subsidiary of Lonza Group Ltd operating within the Lonza Microbial Control business sector, has reached an agreement pursuant to which Sumitomo Seika Chemicals Co., Ltd. of Japan has licensed Arch under certain patents in the United States, Europe, Japan and China covering an advanced method of manufacturing 1, 2 benzisothiazolin 3-one (BIT). Under the agreement, Arch has the right to sub-license the technology to third parties, and to enforce the licensed patents against direct and indirect infringement.
"We are pleased to come to this agreement with Sumitomo Seika," said Mark Kenline of Lonza Microbial Control's Materials Protection business. "BIT is widely used as a preservative in our key market segments, where it is sold under the Proxel trademark, and this licensing agreement enhances our ability to provide our customers with global registrations, security of supply, unparalleled product support, and products manufactured by the best available technology."
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Lonza is amongst the world leaders in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited. Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of theSIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting.
This document was provided by SpecialChem's editor. If you want to share your press
release, please send it to email@example.com.
SpecialChem reserves the right to refuse any article or news item.